Healios KK’s ONE-BRIDGE Trial Data Published in Japan

Healios KK ( (JP:4593) ) has provided an update.

Healios KK announced the publication of clinical data from the ONE-BRIDGE trial in a leading Japanese journal, enhancing the credibility of their application for conditional approval of HLCM051 for ARDS treatment. The study showed promising results, including an extension of ventilator-free days and reduced mortality, supporting the therapeutic potential of their product.

More about Healios KK

Healios KK is a company operating in the regenerative medicine industry, focusing on developing cell therapies for conditions like Acute Respiratory Distress Syndrome (ARDS).

YTD Price Performance: 57.06%

Average Trading Volume: 3,479,307

Technical Sentiment Consensus Rating: Sell

Current Market Cap: Yen27.34B

For detailed information about 4593 stock, go to TipRanks’ Stock Analysis page.